That EngMab buyout? Celgene agreed to pay up to $3B for BCMA-targeting drug
That EngMab buyout deal by Celgene was a little bigger than we first reported at the end of September.
After hearing that Celgene — one of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
